Trinity Biotech plc (NASDAQ:TRIB)’s share price rose 2.4% during mid-day trading on Thursday . The company traded as high as $11.18 and last traded at $10.85, with a volume of 161,589 shares. The stock had previously closed at $10.60.

TRIB has been the subject of a number of research reports. Roth Capital reiterated a “buy” rating on shares of Trinity Biotech plc in a report on Thursday, April 21st. Zacks Investment Research upgraded Trinity Biotech plc from a “sell” rating to a “hold” rating in a report on Wednesday, June 22nd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $18.00.

The firm’s 50-day moving average is $11.11 and its 200 day moving average is $10.99. The company has a market capitalization of $252.66 million and a P/E ratio of 40.64.

Trinity Biotech plc (NASDAQ:TRIB) last released its earnings results on Tuesday, April 19th. The company reported $0.06 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.08 by $0.02. On average, equities analysts expect that Trinity Biotech plc will post $0.21 earnings per share for the current fiscal year.

Several hedge funds have made changes to their positions in the stock. Paradice Investment Management LLC boosted its stake in shares of Trinity Biotech plc by 38.4% in the fourth quarter. Paradice Investment Management LLC now owns 1,373,357 shares of the company’s stock worth $16,151,000 after buying an additional 381,122 shares during the last quarter. Boston Partners boosted its stake in shares of Trinity Biotech plc by 2.8% in the fourth quarter. Boston Partners now owns 1,589,960 shares of the company’s stock worth $18,698,000 after buying an additional 42,590 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Trinity Biotech plc during the fourth quarter worth approximately $13,045,000. Heartland Advisors Inc. boosted its stake in shares of Trinity Biotech plc by 4.0% in the fourth quarter. Heartland Advisors Inc. now owns 1,252,350 shares of the company’s stock worth $14,728,000 after buying an additional 48,630 shares during the last quarter. Finally, US Bancorp DE boosted its stake in shares of Trinity Biotech plc by 103.1% in the fourth quarter. US Bancorp DE now owns 238,825 shares of the company’s stock worth $2,808,000 after buying an additional 121,214 shares during the last quarter.

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.